COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Unmanned vessel Yunfan tracks typhoons up close
- Modern African Makonde sculpture exhibition opens in Changchun
- Exhibitions across Strait memorialize war victory
- Xi and his wife meet Cambodian King, Queen Mother
- Where hooves echo: Xizang's horse racing tradition endures
- Documentary 'The Heritage Guardian' premieres on major media in SCO countries
